• Eric Christianson
• 19 Jan, 2020

The FDA has recently approved two generic versions of apixaban and from the amount of apixaban I’m seeing used in clinical practice, this is a great thing for overall healthcare and drug costs. Here’s the FDA’s statement. Because of this switch to generic apixaban availability as well as the recent 2019 atrial fibrillation guidelines, I anticipate apixaban use to dominate other anticoagulants. Apixaban is not without clinical quirks.
Read more...